QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.

Phase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.

Trial locations(19 sites)

China

Fujian Cancer Hospital, Fuzhou, Fujian

Dongguan People's Hospital, Dongguan, Guangdong

First People's Hospital of Foshan, Foshan, Guangdong

Guangzhou Panyu Central Hospital, Guangzhou, Guangdong

Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong

Zhongshan People's Hospital, Zhongshan, Guangdong

Cancer Hospital of Guangxi Medical University, Nanning, Guangxi

Cancer Hospital of Guizhou Medical University, Guiyang, Guizhou

Hubei Province Cancer Hosiptal, Wuhan, Hubei

Renmin Hospital of Wuhan University, Wuhan, Hubei

Tongji Hospital Affiliated with Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei

Union Hospital Affiliated with Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei

Hunan Cancer Hospital, Changsha, Hunan

Xiangya Hospital of Central South University, Changsha, Hunan

Jiangsu Cancer Hospital, Nanjing, Jiangsu

The Eye and ENT Hospital of Fudan University, Shanghai, Shanghai Municipality

Sichuan Cancer Hospital, Chengdu, Sichuan

Tianjin Medical University Cancer Institute ＆ Hospital, Tianjin, Tianjin Municipality

The First Affiliated Hospital of Xiamen University, Fujian, Xiamen